The role of FluoroDeoxyGlucose-Positron Emission Tomography imaging in clinical stages Ia/IIa Hodgkin's disease

ISRCTN ISRCTN99811594
DOI https://doi.org/10.1186/ISRCTN99811594
ClinicalTrials.gov number NCT00943423
Secondary identifying numbers LRF 02/20
Submission date
20/10/2003
Registration date
21/10/2003
Last edited
26/10/2022
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

https://www.cancerresearchuk.org/about-cancer/find-a-clinical-trial/a-trial-using-pet-scans-to-help-decide-treatment-options-for-early-stage-hodgkins-lymphoma

Contact information

Ms Bilyana Popova
Scientific

Cancer Research UK and UCL Cancer Trials Centre
90 Tottenham Court Road
London
W1T 4TJ
United Kingdom

Email fdg-pet@ctc.ucl.ac.uk

Study information

Study designRandomised controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details below to request a patient information sheet
Scientific titleA randomised phase III trial to determine the role of FluoroDeoxyGlucose-Positron Emission Tomography imaging in clinical stages Ia/IIa Hodgkin's disease
Study acronymFDG-PET
Study objectivesAdded 06/01/2009:
FluoroDeoxyGlucose-Positron Emission Tomography (FDG-PET) negativity after three cycles of adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD) is indicative of a level of response whereby radiotherapy can be safely omitted without significantly compromising the duration of remission for patients with stage Ia/IIa Hodgkin's disease above the diaphragm.

On 05/01/2009 the following changes were made to this trial record:
1. The anticipated end date was changed from 01/10/2003 to 31/12/2009 (correction)
2. The target number of participants was changed from 320 to 400. An ethics approval has been obtained for this amendment.

Other changes are recorded within the relevant fields.
Ethics approval(s)North West Research Ethics Committee, 04/07/2003, ref: 03/8/056. An amendment to the number of participants was approved on 08/08/2008.
Health condition(s) or problem(s) studiedHodgkin's Disease
InterventionPatients with a negative PET scan after three cycles of ABVD treatment will be randomised to involved field radiotherapy or no further treatment.
Intervention typeDrug
Pharmaceutical study type(s)
PhasePhase III
Drug / device / biological / vaccine name(s)Adriamycin (doxorubicin), bleomycin, vinblastine and dacarbazine (ABVD)
Primary outcome measureAdded 05/01/2009:
Three-year progression-free survival.
Secondary outcome measuresAdded 05/01/2009:
1. Incidence of FDG-PET positivity/negativity after three cycles of ABVD
2. Survival (time from date of registration/randomisation to date of death from any cause) and cause of death. Participants will be followed up until death.
3. Incidence and type of second cancers. Participants will be followed up until death.
Overall study start date01/10/2003
Completion date31/12/2009

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants400
Total final enrolment571
Key inclusion criteria1. Aged 16 - 75 years, either sex
2. Histologically confirmed Hodgkin's disease (histology will be reviewed retrospectively by Professor A Jack at the Haematological Malignancy Diagnostic Service in Leeds but please note that this is not required before trial entry)
3. Clinical stages Ia/IIa above the diaphragm with no mediastinal bulk (defined as maximum transverse diameter of mediastinal mass: internal thoracic diameter at level of D5/6 interspace greater than 0.33). Bulky disease at other sites (defined as nodal mass with transverse diameter greater than 10 cm) is acceptable.
4. No previous treatment for Hodgkin's disease
5. No previous malignancy excepting appropriately treated basal cell carcinoma of the skin or carcinoma in situ of the cervix
6. No contraindications to chemotherapy or radiotherapy
7. Patients with reproductive potential: a willingness to use contraception from entry into the study for a period of 6 months
8. Written informed consent
Key exclusion criteria1. Patients with clinical stage Ia Hodgkin's disease with no clinical or computed tomography (CT) evidence of disease after diagnostic biopsy
2. Pregnant or lactating women
3. Severe underlying illness considered likely to make the trial therapy hazardous (for example severe heart disease or lung fibrosis)
4. Patients unwilling to travel to the nearest PET Centre
5. Patients unable to comply with follow-up arrangements
Date of first enrolment01/10/2003
Date of final enrolment31/12/2009

Locations

Countries of recruitment

  • England
  • United Kingdom

Study participating centre

Cancer Research UK and UCL Cancer Trials Centre
London
W1T 4TJ
United Kingdom

Sponsor information

Leukaemia Research Fund (UK)
Charity

43 Great Ormond Street
London
WC1N 3JJ
United Kingdom

Email sgerscher@lrf.org.uk
Website http://www.lrf.org.uk
ROR logo "ROR" https://ror.org/0055acf80

Funders

Funder type

Charity

Leukaemia Research Fund (UK)

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryNot provided at time of registration
Publication and dissemination planNot provided at time of registration
IPD sharing planNot provided at time of registration

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 23/04/2015 14/02/2020 Yes No
Plain English results 26/10/2022 No Yes

Editorial Notes

25/10/2022: Cancer Research UK plain English results link and total final enrolment added.
14/02/2020: ClinicalTrials.gov number and publication reference added.
20/03/2017: No publications found in PubMed, verifying study status with principal investigator.